公开(公告)号：US20150274671A1

公开(公告)日：2015-10-01

申请号：US14434764

申请日：2013-10-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Donald J. P. Pinto ,  Charles G. Clark ,  Michael J. Orwat ,  Leon M. Smith II ,  William R. Ewing

IPC: C07D217/04 ,  C07D409/04 ,  C07D405/04 ,  C07D401/04

CPC classification number: C07D217/04 ,  C07D217/26 ,  C07D401/04 ,  C07D405/04 ,  C07D409/04

Abstract: The present invention provides compounds of Formula (I): (Formula (I)) or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Abstract translation: 本发明提供式（I）的化合物：（式（I））或其立体异构体，其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的因子XIa和/或血浆激肽释放酶的抑制剂。

公开(公告)号：US20180222889A1

公开(公告)日：2018-08-09

申请号：US15750212

申请日：2016-08-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James R. Corte ,  William R. Ewing ,  Donald J.P. Pinto ,  Leon M. Smith II

IPC: C07D403/10 ,  A61P7/02 ,  C07D403/14 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D409/14 ,  C07D413/14 ,  C07D498/04 ,  C07D417/14 ,  C07D487/04 ,  C07D471/10 ,  C07D211/86 ,  C07D401/10 ,  C07D237/14

CPC classification number: C07D403/10 ,  A61P7/02 ,  C07D211/86 ,  C07D237/14 ,  C07D401/10 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D498/04

Abstract: The present invention provides compounds of Formula (I): [INSERT CHEMICAL STRUCTURE HERE] (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US20190016735A1

公开(公告)日：2019-01-17

申请号：US16067619

申请日：2017-01-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Leon M. Smith II ,  Vladimir Ladziata ,  Indawati De Lucca ,  Donald J.P. Pinto ,  Michael J. Orwat ,  Andrew K. Dilger ,  Kumar Balashanmuga Pabbisetty ,  Wu Yang ,  Scott A. Shaw ,  Peter W. Glunz ,  Manoranjan Panda

IPC: C07D513/04 ,  A61P9/10 ,  A61P15/10

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

公开(公告)号：US20160368923A1

公开(公告)日：2016-12-22

申请号：US15221142

申请日：2016-07-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Andrew K. Dilger ,  James R. Corte ,  lndawati De Lucca ,  Tianan Fang ,  Wu Yang ,  Yufeng Wang ,  Kumar Balashanmuga Pabbisetty ,  William R. Ewing ,  Yeheng Zhu ,  Ruth R. Wexler ,  Donald J.P. Pinto ,  Michael J. Orwat ,  Leon M. Smith II

IPC: C07D471/18 ,  C07D519/00 ,  C07F7/08 ,  C07D487/08 ,  C07D471/08

CPC classification number: C07D471/18 ,  C07D471/08 ,  C07D487/08 ,  C07D519/00 ,  C07F7/0814

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract translation: 或立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。